<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624840</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2022.361</org_study_id>
    <nct_id>NCT05624840</nct_id>
  </id_info>
  <brief_title>Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir</brief_title>
  <official_title>Safety and Clinical and Virologic Outcomes in COVID-19 Patients With Chronic Kidney Disease Treated With Nirmatrelvir-ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (COVID-19) but not initially&#xD;
      recommended in patients with severe renal impairment. Increasing observational data have&#xD;
      shown the feasibility of dose-adjusted nirmatrelvir-ritonavir administration in patients with&#xD;
      estimated glomerular filtration rate lower than 30 ml/min/1.73 m^2. The study is planned to&#xD;
      assess the safety, clinical and virologic outcomes of early oral nirmatrevir-ritonavir&#xD;
      treatment of COVID-19 in patients with stage 4 and 5 chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study are to evaluate the safety and clinical and virologic outcomes of&#xD;
      dose-adjusted nirmatrelvir-ritonavir in patients with eGFR lower than 30 ml/min/1.73 m^2.&#xD;
      Patients with eGFR greater than 30 ml/min/1.73 m2 and prescribed nirmatrelvir-ritonavir will&#xD;
      be used for comparison.&#xD;
&#xD;
      In the single-centre study, patients with stage 4 and 5 chronic kidney disease prescribed&#xD;
      early treatment dose-adjusted nirmatrelvir-ritonavir will be assessed for the primary&#xD;
      endponts of adverse events during or after treatment with nirmatrelvir-ritonavir (starting on&#xD;
      or before day 30), serious adverse events and adverse events leading to discontinuation of&#xD;
      nirmatrelvir-ritonavir.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events during or after treatment with nirmatrelvir-ritonavir (starting on or before day 30), serious adverse events and adverse events leading to discontinuation of nirmatrelvir-ritonavir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAT</measure>
    <time_frame>30 days</time_frame>
    <description>Time to negative rapid antigen test result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebound</measure>
    <time_frame>30 days</time_frame>
    <description>Rebound of positive rapid antigen test or polymerase chain reaction PCR up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Clinical Progression Scale CPS</measure>
    <time_frame>30 days</time_frame>
    <description>Time to progression to CPS 5 up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>30 days</time_frame>
    <description>Time to resolution of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic rebound</measure>
    <time_frame>30 days</time_frame>
    <description>Symptomatic rebound (symptomatic again after resolution of symptom with positive RAT or PCR)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Chronic Kidney Disease stage4</condition>
  <condition>Chronc Kidney Disease Stage 5</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nirmatrelvir/ritonavir</intervention_name>
    <description>Nirmatrelvir-ritonavir (Paxlovid)</description>
    <other_name>Paxlovid</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single centre study of 100 adult patients treated with nirmatrelvir-ritonavir for&#xD;
        early COVID-19 disease in the omicron era.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 and above.&#xD;
&#xD;
          -  COVID-19 infection and symptom onset no more than 5 days, with or without prior&#xD;
             vaccination.&#xD;
&#xD;
          -  WHO CPS 1-4&#xD;
&#xD;
          -  Indicated for nirmatrelvir-ritonavir treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients cannot swallow capsules or adhere to protocol.&#xD;
&#xD;
          -  Severe COVID-19 disease, including patients who require oxygen supplement therapy&#xD;
&#xD;
          -  Significant hypersensitivity to nirmatrelvir, ritonavir, or any component of the&#xD;
             formulation&#xD;
&#xD;
          -  Patients require co-administration of drugs that are highly dependent on CYP3A4 for&#xD;
             clearance and cannot be omitted during the treatment period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prince of Wales Hospital, Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <zip>SAR</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Ming Chow, MBChB</last_name>
      <phone>852-26323131</phone>
      <email>Chow_Kai_Ming@alumni.cuhk.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 21, 2022</last_update_submitted>
  <last_update_submitted_qc>November 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chow Kai Ming</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

